Send to

Choose Destination
Sci Rep. 2017 Feb 2;7:41605. doi: 10.1038/srep41605.

Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways.

Author information

Boston University School of Medicine, Arthritis Center/Rheumatology, Boston, MA, USA.
Boston University School of Medicine, Vascular Biology Section, Boston, MA, USA.
Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, USA.
Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, USA.
Boston University School of Medicine, Microbiology, Boston, MA, USA.


Pulmonary arterial hypertension (PAH) is a fatal condition for which there is no cure. Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflammatory agent with a favorable safety record. The goal of this study was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and murine models. We show that DMF treatment is effective in reversing hemodynamic changes, reducing inflammation, oxidative damage, and fibrosis in the experimental models of PAH and lung fibrosis. Our findings indicate that effects of DMF are facilitated by inhibiting pro-inflammatory NFκB, STAT3 and cJUN signaling, as well as βTRCP-dependent degradation of the pro-fibrogenic mediators Sp1, TAZ and β-catenin. These results provide a novel insight into the mechanism of its action. Collectively, preclinical results demonstrate beneficial effects of DMF on key molecular pathways contributing to PAH, and support its testing in PAH treatment in patients.

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

J.S.I. serves as chair of the scientific advisory boards of Tioma Therapeutics (St. Louis, MO) and Radiation Control Technologies, Inc. (Jersey City, NJ).

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center